Cargando…

The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung

Detalles Bibliográficos
Autores principales:	Ichiki, Yoshinobu, Fukuyama, Takashi, Nakanishi, Kozo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354138/ https://www.ncbi.nlm.nih.gov/pubmed/32676343 http://dx.doi.org/10.21037/tlcr.2020.01.14

Ejemplares similares

Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors
por: Ichiki, Yoshinobu, et al.
Publicado: (2022)

Should Lung-Sparing Surgery Be the Standard Procedure for Malignant Pleural Mesothelioma?
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

Relationship between Kita-Kyushu Lung Cancer antigen-1 expression and prognosis of cases with lung squamous cell carcinoma
por: Ichiki, Yoshinobu, et al.
Publicado: (2021)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

An analysis of the immunological tumor microenvironment of primary tumors and regional lymph nodes in squamous cell lung cancer
por: Ichiki, Yoshinobu, et al.
Publicado: (2021)

A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma
por: Fei, Kailun, et al.
Publicado: (2020)

Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
por: Liu, Wei, et al.
Publicado: (2020)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
por: Zhou, Fei, et al.
Publicado: (2020)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis
por: Niu, Zhicheng, et al.
Publicado: (2021)

Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial
por: Sano, Daisuke, et al.
Publicado: (2023)

Commentary: Squamous cell carcinoma of the esophagus: Another target for checkpoint inhibition
por: Whyte, Richard I.
Publicado: (2022)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
por: Jardim, Denis L., et al.
Publicado: (2018)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

COVID-19 and immune checkpoint inhibitors: initial considerations
por: Sullivan, Ryan J, et al.
Publicado: (2020)

Two Types of Immune Checkpoint Inhibitor-related Pancreatitis
por: Ichiki, Tomoko, et al.
Publicado: (2021)

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?
por: Metro, Giulio, et al.
Publicado: (2020)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

First-line immune-chemotherapy combination for squamous NSCLC is already a reality
por: Hendriks, Lizza E. L., et al.
Publicado: (2020)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer
por: Kuo, Chih‐Hsi Scott, et al.
Publicado: (2019)

Utilizing the chest tube insertion site as the site of initial trocar insertion with an optical-access trocar in video-assisted thoracoscopic surgery for spontaneous pneumothorax
por: Goto, Hidenori, et al.
Publicado: (2022)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
por: Haratani, Koji, et al.
Publicado: (2020)

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
por: Bersanelli, Melissa
Publicado: (2020)

How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?
por: Minami, Yasunori, et al.
Publicado: (2022)

Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma
por: Baba, Yoshifumi, et al.
Publicado: (2020)

Sphingomyelin is a prospective metabolic immune checkpoint for natural killer cells
por: Ma, Hongdi, et al.
Publicado: (2023)

Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors
por: Muraro, Elena, et al.
Publicado: (2023)

Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?
por: Wongariyapak, Amarin, et al.
Publicado: (2023)

Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities
por: Jiao, Ruidi, et al.
Publicado: (2019)

Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors
por: Stern, Peter L., et al.
Publicado: (2021)

Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer
por: Iso, Hirokazu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dh3vpjmuq5607mo0dhnbugb6mf